Primary Aldosteronism Panel
Use
This test is intended for individuals who have clinical or suspected primary aldosteronism, especially those suspected to have a familial form, or individuals who exhibit symptoms indicative of the condition with onset before age 20. It is useful for assessing genetic predispositions that may lead to the development of primary aldosteronism, aiding in the diagnosis and management of this condition.
Special Instructions
Ensure accurate selection of specimen type as the requirements differ between platforms (Exome and Genome). STAT testing options are available if faster results are needed, and exome-wide CNV analysis can be added for an additional fee when using the Exome or Genome platform.
Limitations
This test detects mutations in known genes associated with primary aldosteronism using NGS and CNV analysis. However, it may not identify all genetic causes of the disease, especially if they involve genes not included in this panel. The detection of CNVs is restricted to those detectable by exome or genome sequencing platforms. Additionally, any specific sub-genetic variations that impact regulation without altering the sequenced regions will not be identified.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
2-3 weeks
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided